1. Vannuccini S, Clifton VL, Fraser IS et al. Infertility and reproductive disorders: impact of hormonal and inflammatory mechanisms on pregnancy outcome. Hum Reprod Update 2016; 22 (1): 104–15.

2. Johnson NP, Hummelshoj L. World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod 2013; 28 (6): 1552–68.

3. Tanbo T, Fedorcsak P. Endometriosis-associated infertility: aspects of pathophysiological mechanisms and treatment options. Acta Obstet Gynecol Scand 2016. DOI: 10.1111/aogs.13082

4. Dunselman GA, Vermeulen N, Becker C et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014; 29 (3): 400–12.

5. Jacobson TZ, Duffy JM, Barlow D et al. Laparoscopic surgery for subfertility associated with endometriosis. Cochrane Database Syst Rev 2010: CD001398.

6. Duffy JM, Arambage K, Correa FJ et al. Laparoscopic surgery for endometriosis. Cochrane Database Syst Rev 2014: CD011031.

7. Singh SS, Suen MW. Surgery for endometriosis: beyond medical therapies. Fertil Steril 2017; 107 (3): 549–4.

8. Goodman LR, Goldberg JM, Flyckt RL et al. Effect of surgery on ovarian reserve in women with endometriomas, endometriosis and controls. Am J Obstet Gynecol 2016; 215 (589): e1–6.

9. Hamdan M, Dunselman G, Li TC, Cheong Y. The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis. Hum Reprod Update 2015; 21: 809–25.

10. Vercellini P, Somigliana E, Vigano P et al. The effect of second-line surgery on reproductive performance of women with recurrent endometriosis: a systematic review. Acta Obstet Gynecol Scand 2009; 88: 1074–82.

11. Dunselman GA, Vermeulen N, Becker C et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014; 29 (3): 400–12.

12. Hughes E, Brown J, Collins JJ et al. Ovulation suppression for endometriosis. Cochrane Database Syst Rev 2007: CD000155.

13. Sallam HN, Garcia-Velasco JA, Dias S, Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006; 1: CD004635.

14. Takemura Y, Osuga Y, Fujimoto A et al. Increased risk of placenta previa is associated with endometriosis and tubal factor infertility in assisted reproductive technology pregnancy. Gynecol Endocrinol 2013; 29: 113–5.

15. Vercellini P, Parazzini F, Pietropaolo G et al. Pregnancy outcome in women with peritoneal, ovarian and rectovaginal endometriosis: a retrospective cohort study. BJOG 2012; 119: 1538–43.

16. Conti N, Cevenini G, Vannuccini S et al. Women with endometriosis at first pregnancy have an increased risk of adverse obstetric outcome. J Matern Fetal Neonatal Med 2014; 9: 1–4.

17. Fernando S, Breheny S, Jaques AM et al. Preterm birth, ovarian endometrioma, and assisted reproduction technologies. Fertil Steril 2009; 91: 325–30.

18. Leone Roberti Maggiore U, Ferrero S, Mangili G et al. A systematic review on endometriosis during pregnancy: diagnosis, misdiagnosis, complications and outcomes. Hum Reprod Update 2016; 22 (1): 70–103.

19. Aris A. A 12-year cohort study on adverse pregnancy outcomes in Eastern Townships of Canada: impact of endometriosis. Gynecol Endocrinol 2014; 30: 34–7.

20. Hashimoto A, Iriyama T, Sayama S et al. Adenomyosis and adverse perinatal outcomes: increased risk of second trimester miscarriage, preeclampsia, and placental malposition. J Matern Fetal Neonatal Med 2017 Feb 9; p. 1–6.

21. Maheshwari A, Gurunath S, Fatima F, Bhattacharya S. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update 2012; 18 (4): 374–92.

22. Vigano P, Corti L, Berlanda N. Beyond infertility: obstetrical and postpartum complications associated with endometriosis and adenomyosis. Fertil Steril 2015; 104 (4): 802–12.

23. Takebayashi A, Kimura F, Kishi Y. The association between endometriosis and chronic endometritis. PLoS One 2014; 9 (2): e88354.

24. McQueen DB, Bernardi LA, Stephenson MD. Chronic endometritis in women with recurrent early pregnancy loss and/or fetal demise. Fertil Steril 2014; 101 (4): 1026–30.

25. Cicinelli E, Matteo M, Tinelli R. Prevalence of chronic endometritis in repeated unexplained implantation failure and the IVF success rate after antibiotic therapy. Hum Reprod 2015; 30 (2): 323–30.

26. Yang R, Du X, Wang Y et al. The hysteroscopy and histological diagnosis and treatment value of chronic endometritis in recurrent implantation failure patients. Arch Gynecol Obstet 2014; 289: 1363–9.

27. Радзинский В.Е., Киселев В.И., Муйжнек Е.Л. и др. Хронический эндометрит и фертильность: новые ответы. Терапевтические возможности преодоления хронического воспаления в эндометрии и улучшения фертильности: информационный бюллетень. М.: StatusPraesens, 2016. / Radzinskii V.E., Kiselev V.I., Muizhnek E.L. i dr. Khronicheskii endometrit i fertil'nost': novye otvety. Terapevticheskie vozmozhnosti preodoleniia khronicheskogo vospaleniia v endometrii i uluchsheniia fertil'nosti: informatsionnyi biulleten'. M.: StatusPraesens, 2016. [Russian]

28. Balen AH, Morley LC, Misso M et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 2016; 22 (6): 687–708.

29. Goodman NF et al. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome – PART 2. Endocr Pract 2015; 21 (12): 1415–26.

30. Yu HF, Chen HS, Rao DP, Gong J. Association between polycystic ovary syndrome and the risk of pregnancy complications: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2016; 95 (51): e4863.

31. Klevedal C, Turkmen S. Fetal-maternal outcomes and complications in pregnant women with polycystic ovary syndrome. Minerva Ginecol 2017; 69 (2): 141–9.

32. Li YY, Ye SQ, Zhong ZH et al. Associations between maternal BMI as well as glucose tolerance and adverse pregnancy outcomes in women with polycystic ovary syndrome. Gynecol Endocrinol 2017; 33 (4): 328–31.

33. Klenov VE, Jungheim ES. Obesity and reproductive function: a review of the evidence. Curr Opin Obstet Gynecol 2014; 26: 455–60.

34. Moran L. Weight management to improve outcomes in infertility. Transforming reproductive medicine worldwide. Birmingham: American Society for Reproductive Medicine, 2013; p. 66–73.

35. Kort JD, Winget C, Kim SH, Lathi RB. A retrospective cohort study to evaluate the impact of meaningful weight loss on fertility outcomes in an overweight population with infertility. Fertil Steril 2014; 101 (5): 1400–3.

36. Garvey WT, Mechanick JI, Brett EM et al. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Assosiation of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for medical care of patients with obesity. Edocr Pract 2016; Suppl 3: 1–203.

37. Cornthwaite K, Jefferys A, Lenguerrand E et al. Pregnancy after weight loss surgery: a commentary. BJOG 2016; 123: 165–70.

38. Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome. Cochrane Database Syst Rev 2016; 12: CD002249.

39. Franik S, Kremer JA, Nelen WL. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2014; 2: CD010287.

40. Legro RS, Arslanian SA, Ehrmann DA. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98 (12): 4565–92.

41. Conti N, Tosti C, Pinzauti S et al. Uterine fibroids affect pregnancy outcome in women over 30 years old: role of other risk factors. J Matern Fetal Neonatal Med 2013; 26: 584–7.

42. Shavell VI, Thakur M, Sawant A et al. Adverse obstetric outcomes associated with sonographically identified large uterine fibroids. Fertil Steril 2012; 97: 107–10.

43. Lam SJ, Best S, Kumar S. The impact of fibroid characteristics on pregnancy outcome. Am J Obstet Gynecol 2014; 211: 395.

44. Deveer M, Deveer R, Engin-Ustun Y et al. Comparison of pregnancy outcomes in different localizations of uterine fibroids. Clin Exp Obstet Gynecol 2012; 39: 516–8.

45. Cheung A, Sierra S, Carranza-Mamane B et al. The management of uterine fibroids in women with otherwise unexplained infertility. J Obstet Gynaecol Can 2015; 37 (3): 277–85.

46. Palmer JE, Perunovic B, Tidy JA. Endometrial hyperplasia. Obstet Gynaecologist 2008; 10: 211–6.

47. Owens GL, Kitchener HC. Premalignant disease in the genital tract in pregnancy. Best Pract Res Clin Obstet Gynaecol 2016; 33: 33–43.

48. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125: 477–82.

49. Poon LC, Savvas M, Zamblera D et al. Large loop excision of transformation zone and cervical length in the prediction of spontaneous preterm delivery. BJOG: an international journal of obstetrics and gynaecology 2012; 119 (6): 692–8.

50. Kyrgiou M, Mitra A, Arbyn M et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ 2014; 349: g6192.

51. Kyrgiou M, Athanasiou A, Paraskevaidi M et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 2016; 354: i3633.

52. Kindinger LM, Kyrgiou M, MacIntyre DA. Preterm Birth Prevention Post-Conization: A Model of Cervical Length Screening with Targeted Cerclage. PLoS One 2016; 11 (11): e0163793.

53. Balakumar P, Nyo YH, Renushia R, Raaginey D. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacol Res 2014; 87: 144–50.

54. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.

55. Okoroh EM, Hooper WC, Atrash HK et al. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003–2008. Am J Obstet Gynecol 2012; 207 (5), 377: e1–8.

56. Okoroh EM, Boulet SL, George MG et al. Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome. Thromb Res 2015; 136 (6): 1165–8.

57. Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res 2016; 137: 11–6.

58. Yamanaka A, Kimura F, Yoshida T et al. Dysfunctional coagulation and fibrinolysis systems due to adenomyosis is a possible cause of thrombosis and menorrhagia. Eur J Obstet Gynecol Reprod Biol 2016; 204: 99–103. DOI: 10.1016/j.ejogrb.2016.07.499

59. Eisert WG. Dipyridamole in antithrombotic treatment. Adv Cardiol 2012; 47: 78–86.

60. Santanam N, Kavtaradze N, Murphy A et al. Antioxidant supplementation reduces endometriosis-related pelvic pain in humans. Transl Res 2013; 161 (3): 189–95. DOI: 10.1016/j.trsl.2012.05.001

61. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem 2015; 15 (9): 822–9.

62. Сидорова И.С., Леваков С.А., Унанян А.Л. Комплексная консервативная терапия миомы матки в сочетании с аденомиозом: применение препарата «Курантил®». Consilium Medicum. 2007; 9 (6): 21–4. / Sidorova I.S., Levakov S.A., Unanian A.L. Kompleksnaia konservativnaia terapiia miomy matki v sochetanii s adenomiozom: primenenie preparata «Kurantil». Consilium Medicum. 2007; 9 (6): 21–4. [in Russian]

63. Сидорова И.С., Унанян А.Л., Власов Р.С. Роль антиагрегантной терапии в лечении хронического эндометрита. Гинекология. 2009; 11 (4): 33–6. / Sidorova I.S., Unanian A.L., Vlasov R.S. Rol' antiagregantnoi terapii v lechenii khronicheskogo endometrita. Gynecology. 2009; 11 (4): 33–6. [in Russian] 

64. Унанян А.Л., Аракелов С.Э., Полонская Л.С. и др. Плацентарная недостаточность: особенности этиопатогенеза, терапии и профилактики. Consilium Medicum. 2015; 17 (6): 37–40. / Unanian A.L., Arakelov S.E., Polonskaia L.S. i dr. Platsentarnaia nedostatochnost': osobennosti etiopatogeneza, terapii i profilaktiki. Consilium Medicum. 2015; 17 (6): 37–40. [in Russian]

65. Kelly R, Holzman C, Senagore P et al. Placental vascular pathology findings and pathways of preterm delivery. Am J Epidemiol 2009; 170: 148–58.

66. Van Vliet EO, Askie LA, Mol BW, Oudijk MA. Antiplatelet Agents and the Prevention of Spontaneous Preterm Birth: A Systematic Review and Meta-analysis. Obstet Gynecol 2017; 129 (2): 327–36.

67. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; 2: CD004659.